Biotron Expands with Sedarex Acquisition and Reports Strong Preclinical HBV Drug Data

The latest update is out from Biotron ( (AU:BIT) ).

Biotron Limited’s December 2025 quarter was marked by the completed acquisition of unlisted public company Sedarex Limited, which owns global patents for SedRx, a safer next-generation general anaesthetic based on alfaxalone with improved safety and cognitive outcomes and potential expedited regulatory pathways in the US and Europe. This strategic move, supported by a $1 million placement and a partially completed rights issue that has so far raised $645,861, broadens Biotron’s pipeline into late-stage anaesthesia and neuroscience indications, enhances its asset base and diversification, and is accompanied by board strengthening through the appointment of Dr Paul Kasian as a Non-Executive Director. In parallel, the company reported promising preclinical data for its lead Hepatitis B drug BIT-HBV001, which showed strong antiviral activity in two animal models, superior performance to standard-of-care Tenofovir on multiple replication markers, and synergistic effects in combination studies, and it filed a new patent covering BIT-HBV001 and related compounds, reinforcing its intellectual property position and potential competitive advantage in HBV therapeutics.

The most recent analyst rating on (AU:BIT) stock is a Sell with a A$0.01 price target. To see the full list of analyst forecasts on Biotron stock, see the AU:BIT Stock Forecast page.

More about Biotron

Biotron Limited is an Australian biotechnology company focused on developing antiviral therapeutics, with a portfolio of small-molecule drugs targeting serious viral infections such as Hepatitis B. The company maintains a broad patent portfolio, conducts preclinical and clinical research, and is pursuing commercialisation of its lead candidates in collaboration with US-based C14 Consulting Group.

Technical Sentiment Signal: Sell

Current Market Cap: A$7.23M

See more data about BIT stock on TipRanks’ Stock Analysis page.